Omeros Abandons Kidney Disease Therapy After Failed Trial

Omeros' drug candidate for immunoglobulin A nephropathy (IgAN) failed a Phase III study, causing the company's stock price to drop by nearly half. The late-stage failure is a setback for Omeros' pipeline-in-a-product plans for narsoplimab, and as a result, the ARTEMIS-IGAN study will be discontinued. The trial did not achieve statistical significance in reducing elevated protein levels in urine compared to the placebo.